BioSpace News Archive

-- Monotherapy and combination studies continue to demonstrate best - in - class potential of MDNA11 -- B ispecific IL-2/IL-13 Superkine demonstrates the potential to treat immunologically “cold” tumors

First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMO), today announced plans to significantly expand its biology capabilities at its integrated R&D campus in Hyderabad, India with a dedicated 75,000 sq. ft. facility and an augmented team of 170 biologists.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2020 , on Thursday, November 5, 2020 before the opening of the financial markets.

INOVIO (NASDAQ: INO) announced today that third quarter 2020 financial results will be released after the market close on November 9, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA M

The National Kidney Foundation (NKF) is pleased to announce that Dr. Paul M. Palevsky, a nephrologist and Professor of Medicine, University of Pittsburgh School of Medicine and Chief of Kidney Medicine at the VA Pittsburgh Healthcare System, has begun his two-year term as president of NKF’s Board of Directors.

James Aggen, PhD has joined Circle Pharma as its Vice President of Medicinal Chemistry and will lead Circle’s chemistry team in its discovery and development of macrocycle therapeutics against intractable cancer targets.

Foldax® , Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted approval to expand the U.S. clinical study of the Tria™ surgical aortic heart valve. This next stage of enrollment is expected to begin within the next month. “We are excited to expand enrollment in this U.S. clinical study to gain additional clinical experience with the Tria valve,” stated Frank Shannon, MD, Chief of Cardiov

The initial six approved formulations were developed to enhance human performance and cognitive health

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has received the second tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc.